| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 10, 2026 | Biocaptiva Secures £1.58M, Unveils Pioneering Liquid Biopsy Tech in US | Biocaptiva, an Edinburgh biotech firm, secured £1.58M in new funding. They launched their innovative msX magnetic bead technology in the US. This platform extracts cell-free DNA directly from whole blood. It eliminates traditional liquid bi... |
| Mar 9, 2026 | University of Edinburgh biotech spin-out BIOCAPTIVA raises £1.58M | University of Edinburgh spin-out BIOCAPTIVA has raised £1.58 million in a new funding round and launched its first product in the US.
BIOCAPTIVA’s novel magnetic bead technology is designed to solve one of liquid biopsy’s biggest bottleneck... |
| Nov 12, 2025 | Laboratory Economics Issues Research Report on U.S. Anatomic Pathology Market | Laboratory Economics has just published the most comprehensive and detailed market research report available on the U.S. Anatomic Pathology Market. This is an ideal resource for preparing business plans and market strategies.
POUGHKEEPSIE, ... |
| Sep 11, 2025 | Chris Smith new CEO of Laborie | Chris Smith new CEO of Laborie
Thu, Sep 11, 2025 08:15 CET Report this content
Laborie’s Board of Directors has appointed Chris Smith new CEO of Laborie, effective September 22, 2025. Chris Smith succeeds Michael Frazzette, who has decided ... |
| Mar 10, 2025 | Cambridge Innovation Capital: £100 Million Opportunity Fund Closed | Cambridge Innovation Capital (CIC), a leading venture capital firm embedded in the Cambridge ecosystem, announced it has launched a new £100 million Opportunity Fund – which is anchored by Aviva Investors and British Patient Capital – to in... |
| Feb 24, 2025 | Cambridge Innovation Capital launches £100m Opportunity Fund | Aviva Investors and British Patient Capital lead investment into new growth fund addressing the UK’s scale-up funding gap.
24 February 2025, Cambridge, UK — Cambridge Innovation Capital (CIC), the leading venture capital firm embedded in th... |
| Feb 24, 2025 | Cambridge Innovation Capital launches £100M Fund for deeptech and life sciences | Cambridge Innovation Capital (CIC) has today launched a new £100 million Opportunity Fund to invest in growth stage deep tech and life sciences companies.
With up to £20 million per investment into later-stage rounds of deep tech and life s... |
| May 6, 2024 | Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024 | Researchers Used Komodo’s Healthcare Map to Uncover Insights Across Oncology, Women’s Health, Mental Health, Neurology, and more
Komodo Insights Power Three Studies Named Finalists for ISPOR 2024 Research Presentation Awards
SAN FRANCISCO &... |
| Apr 6, 2023 | NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023 | FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. NEO, a leading provider of oncology testing and global contract research services, announced today that the company and its collaborators will present a total of nine abstracts ... |
| Aug 16, 2022 | NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FT. MYERS, FL / ACCESSWIRE / August 16, 2022 / NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, today announced, as required by the Nasdaq Listing Rules, equity inducement awards ... |
| Jul 28, 2022 | Slone Partners Places George Cardoza as Chief Executive Officer at AccuraGen | “George Cardoza is a highly accomplished financial and operations leader with a solid track record of success in the life sciences industry,” said Slone Partners President Tara Kochis.
SOUTH RIDING, Va. (PRWEB) July 28, 2022
Slone Partners,... |
| Jun 3, 2022 | NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory | CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D
FORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, ... |
| Jun 3, 2022 | NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences | FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be partici... |
| Apr 27, 2022 | NeoGenomics Reports Revenue of $117 Million in the First Quarter | First-Quarter 2022 Results
Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3%
Clinical Services revenue increased 2% to $99 million; excluding 2021 COVID-19 PCR ... |
| Apr 11, 2022 | NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D | NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companies
FORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO... |
| Apr 8, 2022 | NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022 | FT. MYERS, FL / ACCESSWIRE / April 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2022, financ... |
| Jan 11, 2022 | NeoGenomics : Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program | January 11, 2022
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer... |
| Nov 4, 2021 | NeoGenomics Reports Revenue of $121 Million in the Third Quarter - Form 8-K | NeoGenomics Reports Revenue of $121 Million
in the Third Quarter
Third-Quarter 2021 Results and Highlights:
•Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 mil... |
| Nov 4, 2021 | NeoGenomics Announces Leadership Team Transition | November 4, 2021
NeoGenomics Announces Leadership Team Transition
FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract res... |
| Nov 4, 2021 | NeoGenomics Reports Revenue of $121 Million in the Third Quarter | November 4, 2021
NeoGenomics Reports Revenue of $121 Million in the Third Quarter
Third-Quarter 2021 Results and Highlights:
Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services re... |
| Oct 19, 2021 | NeoGenomics' : Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays | October 19, 2021
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
Two clinical studies including interventional RaDaR™ study
FT. MYER... |
| Oct 13, 2021 | NeoGenomics : Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year - Form 8-K | Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year
Ft. Myers, Florida - October 12, 2021 - NeoGeno... |
| Oct 12, 2021 | NeoGenomics : Announces Board of Directors' Transition | October 12, 2021
NeoGenomics Announces Board of Directors' Transition
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors befo... |
| Jun 18, 2021 | NeoGenomics completes Inivata acquisition | NeoGenomics completes Inivata acquisition
Combining best-in-class liquid biopsy technology with leading community oncology platform
Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing mar... |
| May 5, 2021 | NEOGENOMICS, INC.
NeoGenomics : to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform | May 5, 2021
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market
NeoGe... |
| May 5, 2021 | Cambridge Innovation Capital announces acquisition of portfolio company Inivata | Cambridge Innovation Capital announces acquisition of portfolio company Inivata
Cambridge Innovation Capital (CIC), the venture capital investor focused on IP-rich deep technology and life science businesses in the Cambridge ecosystem, toda... |
| May 5, 2021 | US giant swallows rest of Inivata in $415m acquisition | US giant swallows rest of Inivata in $415m acquisition
Business Weekly article | By Tony Quested
NASDAQ powerhouse NeoGenomics Inc has exercised its right to hoover up the whole of Cambridge liquid biopsy specialist Inivata.
Having made a $... |
| May 5, 2021 | NEOGENOMICS, INC.
NeoGenomics : Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market | -Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market
-NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million
-Completes $200 million strategic fina... |
| Apr 19, 2021 | NEOGENOMICS, INC.
NeoGenomics : Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients | April 19, 2021
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
SGT Program will provide KRAS G12C testing to eligible pati... |
| Mar 16, 2021 | Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study | NEW YORK and FORT MYERS, Fla., March 16, 2021 /PRNewswire/ -- Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, I... |
| Feb 14, 2021 | Three Small Cap Stocks With Healthy Price Action | One tenet of the efficient markets hypothesis is that small caps, over time, outperform their larger peers. |
| Jun 29, 2020 | Inivata's US commercial launch of InVisionFirst®-Lung | Inivata’s liquid biopsy test for advanced non-small cell lung cancer is now available through NeoGenomics in the US
Research Triangle Park, NC, USA and Cambridge, UK – Inivata, a leader in liquid biopsy, today announces that NeoGenomics, In... |
| May 26, 2020 | Portfolio company Inivata announces collaboration and investment from NeoGenomics | Cambridge Innovation Capital portfolio company Inivata announces strategic collaboration and investment from NeoGenomics
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading... |
| May 26, 2020 | CIC portfolio company Inivata announces strategic collaboration and investment from NeoGenomics | CIC portfolio company Inivata announces strategic collaboration and investment from NeoGenomics
26-05-2020
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in ... |
| May 26, 2020 | CIC portfolio company Inivata announces strategic collaboration and investment from NeoGenomics | Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, is pleased to note that portfolio company Inivata, a leader in liquid biopsy, has ... |
| May 26, 2020 | Inivata Announces Strategic Collaboration and Investment from NeoGenomics | NeoGenomics will commercialize Inivata’s InVisionFirst®-Lung liquid biopsy test in the United States. Equity investment in Inivata to support further development of leading liquid biopsy technology and products
Research Triangle Park, NC, U... |
| Oct 29, 2018 | NeoGenomics to Acquire 1315 Capital-backed Genoptix for $125M | FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to acquire Genoptix, Inc. for ... |
| Oct 29, 2018 | NeoGenomics to Acquire Ampersand Capital-backed Genoptix for $125M | FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to acquire Genoptix, Inc. for ... |
| Oct 29, 2018 | NeoGenomics to Acquire Genoptix for $125M | FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to acquire Genoptix, Inc. for ... |
| Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study | NEW YORK and FORT MYERS, Fla., March 16, 2021 /PRNewswire/ -- Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, I... |
